News CRISPR Therapeutics plans Nasdaq launch CRISPR Therapeutics, the Swiss genome-editing company, has filed for a $90 million initial public offering.
Articles Never mind the chill, biotech IPO winter will pass After two giddy years of continuous growth, biotech got a rude awakening in late 2015, but many remain confident in the sector's growth potential, writes Andrew McConaghie.
News Circassia leads UK biotech funding success Three separate fund-raising rounds - headed by Circassia's £275 million placing and open offer - give a further indication of the revival in the
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
